respiratory symptoms. (The H5N1 virus is also able to infect cells deep in the lungs with receptor type a2-3 but cannot infect cells with receptor type a2-6 making it less contagious than H1N1/09.) , most people infected by this flu suffered a mild illness, but the small minority hospitalized were often severely ill. Arand Kumar, an intensive care expert at the University of Manitoba, Winnipeg, Canada, said "this pandemic is like two diseases; either you're off work for a few days or you go to hospital, often to the intensive-care unit (ICU). There's no middle ground." In the southern hemisphere 15 to 33% of hospitalized cases went to the ICU in July and August 2009. Unlike H5N1 avian flu and SARS which provoke a runaway body-wide immune response, H1N1/09 destroys the lungs' alveoli, often causing acute respiratory distress syndrome, which kills in half of all cases. Preliminary research suggests that severity is linked to a genetic variation in immune systems. From April 2009 to November 2009, 3,900 people died of the H1N1 pandemic virus in the U.S. This is sometimes compared to the 36,000 people per year who die from the "common flu", mostly in winter, although this number is an estimate. The death rate of H1N1 in the U.S. was calculated as less than 0.02% from November 2009 figures from the CDC, and has been explicitly calculated as 0.026% in England. Vaccine A study at the U.S. Centers for Disease Control and Prevention published in May 2009 found that children had no preexisting immunity to the new strain but that adults, particularly those older than 60, had some degree of immunity. Children showed no cross-reactive antibody reaction to the new strain, adults aged 18 to 60 had 6–9%, and older adults 33%. While it has been thought that these findings suggest the partial immunity in older adults may be due to previous exposure to similar seasonal influenza viruses, a November 2009 study of a rural unvaccinated population in China found only a 0.3% cross-reactive antibody reaction to the H1N1 strain, suggesting that previous vaccinations for seasonal flu and not exposure may have resulted in the immunity found in the older U.S. population. Production may be three billion doses per year rather than the earlier estimate of five billion. Evolutionary potential On May 22, 2009, World Health Organization (WHO) Director-General Margaret Chan said the virus must be closely monitored in